Back To Index Last Article Next Article

Japan. J. Pharmacol. 60, 315-321 (1992)

Protective Activity of Silipide (Siliphos) on Liver Damage in Rodents

Marisa Conti, Salvatore Malandrino and Maria Jose Magistretti

Inverni della Beffa Research and Development Laboratiories, via Ripamonti 99, Milan Italy

See National Library of Medicine Citation

The aim of this study was to assess the effect of the silipide (Siliphos) against liver damage induced by different agents.

The results of this study showed a significant and dose related protective activity against liver damage induced by toxic agents with different mechanisms of action. One of the poisons tested against was galactosomine which mimics hepatitis in its effect on the liver.

The constituents of silipide (Siliphos), on their own, were devoid of any significant activity at doses equivalent to those contained in the active doses of silipide (Siliphos).

The oral efficacy of silipide (Siliphos) and the lack of activity of the uncomplexed silybin indicate that silybin reaches active concentrations at the site of action only when administered as a complex. (1, 2)

Favorable results of preliminary clinical trials (3,4) indicate that silipide (Siliphos) can be considered as a promising new therapeutic agent for the treatment of hepatic disorders.


Morazzoni, P, Magistretti, M.J., Giachetti, C. and Zanolo, G.: Comparative bioavailability of IdB 1016 (Siliphos), a new flavanolignan complex , in rats. Eur. J. Drug Metab. Parmacokinet. 17, 39-44 (1992)

Barzaghi, N., Crema, F., Gatti, G., Pifferi, G. and Perucca, E.: Pharmacokinetic studies on IdB 1016, a silybiin-phosphatidylcholine complex, in healthy human subjects. Eur. J. Drug Metab. Pharmacokinet. 15, 333-338 (1990)

Marena, C. And Lampertico, M.: Preliminary clinical development of silipide (Siliphos): a new complex of silybin in toxic liver disorders. Planta Med. 57, A124-A125 (1991)

Buzzelli, G., Mascarella, S., Giusti, A., Marra, F., Pifferi, G., Marena, C. and Gentilini, P.: Free radical scavenging effects of silybin-phosphatidylcholine (Siliphos) in pationes with chronic liver disease, preliminary results. Abstracts of 26th meeting "European Association for the Study of the Liver", September 1991, Palma de Mallorca (Spain), S103 (1991)

© 2012 Natural Wellness®. All rights reserved.

This website is brought to you byNatural Wellness®,
providing tools and ideas for optimum health.
Contact Us:
Questions? Contact us by phone during our regular business hours, Mon-Fri, 9am to 5pm EST.
800-364-5722 (Toll Free)
845-361-3900 (NY Area)
Risk-Free Guarantee:
You must be 100% satisfied. If not, we'll replace, exchange, or send you a refund or credit your account for unopened merchandise.

* This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Natural Wellness has developed certain nutritional supplements to meet the specified needs of our customers. These products are not intended to diagnose, treat, cure, or prevent a disease, but rather are dietary supplements intended solely for nutritional support. These statements have not been evaluated by the Food and Drug Administration. Testimonials reflect the personal experience of each person quoted. Individual results may vary. The information provided on this site is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. Please consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem.